Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M.   Garrison Louis P.   Miller Lesley-Ann   Hou Likun   Blickensderfer Amy   Zagar Anthony   Stanley Shelley   Bhargava Anuj   Wade Rolin   Herman William H.  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2335-2342

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 689-698

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite